Literature DB >> 16825395

Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.

Elias K Halvas1, Grace M Aldrovandi, Peter Balfe, Ingrid A Beck, Valerie F Boltz, John M Coffin, Lisa M Frenkel, J Darren Hazelwood, Victoria A Johnson, Mary Kearney, Andrea Kovacs, Daniel R Kuritzkes, Karin J Metzner, Dwight V Nissley, Marek Nowicki, Sarah Palmer, Rainer Ziermann, Richard Y Zhao, Cheryl L Jennings, James Bremer, Don Brambilla, John W Mellors.   

Abstract

We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16825395      PMCID： PMC1489464          DOI： 10.1128/JCM.00449-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  19 in total

1.  Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.

Authors:  C Delaugerre; M A Valantin; M Mouroux; M Bonmarchand; G Carcelain; C Duvivier; R Tubiana; A Simon; F Bricaire; H Agut; B Autran; C Katlama; V Calvez
Journal:  AIDS       Date:  2001-11-09       Impact factor: 4.177

2.  Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J.

Authors:  E Fontaine; C Riva; M Peeters; J C Schmit; E Delaporte; K Van Laethem; K Van Vaerenbergh; J Snoeck; E Van Wijngaerden; E De Clercq; M Van Ranst; A M Vandamme
Journal:  J Acquir Immune Defic Syndr       Date:  2001-11-01       Impact factor: 3.731

3.  Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype.

Authors:  Jacques Izopet; Corinne Souyris; Allan Hance; Karine Sandres-Sauné; Muriel Alvarez; Christophe Pasquier; François Clavel; Jacqueline Puel; Patrice Massip
Journal:  J Infect Dis       Date:  2002-04-30       Impact factor: 5.226

4.  Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.

Authors:  D O'Meara; K Wilbe; T Leitner; B Hejdeman; J Albert; J Lundeberg
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

5.  Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Authors:  A J Hance; V Lemiale; J Izopet; D Lecossier; V Joly; P Massip; F Mammano; D Descamps; F Brun-Vézinet; F Clavel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

7.  Analysis of heterogeneous viral populations by direct DNA sequencing.

Authors:  T Leitner; E Halapi; G Scarlatti; P Rossi; J Albert; E M Fenyö; M Uhlén
Journal:  Biotechniques       Date:  1993-07       Impact factor: 1.993

8.  Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.

Authors:  Rob Schuurman; Donald Brambilla; Tom de Groot; Diana Huang; Sally Land; James Bremer; Ireen Benders; Charles A B Boucher
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-01       Impact factor: 2.205

9.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors:  Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

10.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.

Authors:  Karin J Metzner; Sebastian Bonhoeffer; Marek Fischer; Rose Karanicolas; Kristina Allers; Beda Joos; Rainer Weber; Bernard Hirschel; Leondios G Kostrikis; Huldrych F Günthard
Journal:  J Infect Dis       Date:  2003-11-03       Impact factor: 5.226
View more
  61 in total

1.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Authors:  Gillian M Hunt; Ashraf Coovadia; Elaine J Abrams; Gayle Sherman; Tammy Meyers; Lynn Morris; Louise Kuhn
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

2.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

Review 3.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.

Authors:  Michelle Marcial; Jing Lu; Steven G Deeks; Rainer Ziermann; Daniel R Kuritzkes
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

5.  MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.

Authors:  Evguenia S Svarovskaia; Michael J Moser; Andrew S Bae; James R Prudent; Michael D Miller; Katyna Borroto-Esoda
Journal:  J Clin Microbiol       Date:  2006-09-27       Impact factor: 5.948

6.  Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.

Authors:  Roger Paredes; Vincent C Marconi; Thomas B Campbell; Daniel R Kuritzkes
Journal:  J Virol Methods       Date:  2007-07-26       Impact factor: 2.014

7.  Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.

Authors:  Christopher F Rowley; Christian L Boutwell; Shahin Lockman; M Essex
Journal:  J Virol Methods       Date:  2008-03-04       Impact factor: 2.014

8.  Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

Authors:  Richard M Gibson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

Review 9.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

10.  Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design.

Authors:  Valerie F Boltz; Frank Maldarelli; Neil Martinson; Lynn Morris; James A McIntyre; Glenda Gray; Mark J Hopley; Toshio Kimura; Douglas L Mayers; Patrick Robinson; John W Mellors; John M Coffin; Sarah E Palmer
Journal:  J Virol Methods       Date:  2009-12-03       Impact factor: 2.014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.